Total
0
Shares
Image Sourced ShutterStock
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Healthcare technology company HomeStay Care has launched its new business to consumer market offer which will allow consumers to buy its technology directly from the webstore
  • The webstore will enable buyers to learn about a product, its functions and uses before purchasing
  • It also announced the new generation of the HomeStay app which will be launched by the end of July 2019

HomeStay Care has launched a B2C (business to consumer) market offer which will allow consumers to buy its technology directly via the webstore.

The webstore is a key feature in the new B2C channel to expand its distribution footprint. It consists of an easy to use website for consumers, family and friends to review and select an expanded product range.

It has high resolution photos and videos, technical specifications and tutorials so customers can learn about the product they are buying and how to use it.

HomeStay provides digital platforms to older Australians and those living with a disability to allow them to stay in their own homes for longer. Its Intelligent Home platform uses data analysis and human monitoring to determine the residents’ routine and detect anomalies.

This information allows for better decision-making by care providers allowing for more focused services.

The Australian Bureau of Statistics estimates there are 4.1 million disabled Australians funded federally and that there are also 3.7 million that are 65 or older.

“Allowing these people to directly access the technology solutions that make a difference to their individual needs, rather than needing to go through third-party providers, will be a key reason of the success of this new direct B2C offer,” HomeStay CEO Philippa Lewis said.

HomeStay has also announced the launch of the next generation of its HomeStay Connect app which is the user interface that works in conjunction with the Intelligent Home technology.

HomeStay Connect provides enhanced user experiences, additional insights and real-time interaction to family members and carers which gives the clients more independence.

It provides client activity information and instant alerts for family members or carers via their smartphone, tablet or computer.

For this new generation HomeStay has reconfigured several features such as providing a more natural dashboard interface and display. It also incorporates additional activities that weren’t there before such as instant dialling to emergency services, text and email notifications, and activity logs.

The newly update app is fully customisable which allows users to use as little or as much of the functions as they require.

“We are extremely proud to be launching the next generation HomeStay Connect app as it is a central piece of the HomeStay Intelligent Home platform,” Philippa said.

“The modular, customisable approach to technology ensures support for the individual needs of clients, their carers and families and strongly aligns with our strategic approach to assist elderly Australians and those with intellectual disabilities to live independently and with dignity.”

This app will be provided to new users and will be rolled out as an update to current users by the end of July 2019.

HSC by the numbers
More From The Market Herald
Race Oncology (ASX:RAC) - CEO, Phillip Lynch

" Race Oncology (ASX:RAC) posts nominal decline in cash

Race Oncology (RAC) has posted a nominal decline in cash and equivalents as of 30 September 2021 to $8.94 million, down from $9.32...
Prescient Therapeutics (ASX:PTX) - Managing Director and CEO, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) logs timely progress across anti-cancer programs in Q3

Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs after wrapping up the September quarter with $14.8...
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) highlights trial progress in September quarterly

Neuren Pharmaceuticals (NEU) has released its September quarterly report, highlighting the progress with its upcoming clinical trials.

" Invion (ASX:IVX) sees complete regression of tumours in breast cancer trial

Invion (IVX) shares have soared following its latest trial results, demonstrating a complete regression in tumours following in vivo treatment.